Research brief
Recent genetic research has highlightd the importance of microglia, the brain's immune cells, in the development of late-onset Alzheimer's disease. A study using human induced pluripotent stem cell (iPSC) models has shed light on how genetic risk factors influence microglial function. Researchers examined microglia derived from individuals with varying genetic risks for Alzheimer's, finding significant functional deficits in those with higher risk. This study provides a promising avenue for exploring Alzheimer's mechanisms and potential treatments.
Key points
- iPSC models reveal microglial dysfunction in Alzheimer's.
- High genetic risk linked to impaired immune response.
- Potential platform for future Alzheimer's therapies.
Microglial Role in Alzheimer's
Microglia, the brain's primary immune cells, are increasingly seen as key players in the development of Alzheimer's disease, particularly its late-onset form. Genetic studies have pointed to variations in microglial function as contributors to the disease's progression. This study used human iPSC-derived microglia to explore these variations, focusing on individuals with different genetic risk profiles for Alzheimer's.
Functional Deficits in High-Risk Microglia
The research found significant impairments in microglial function among those with a high polygenic risk for Alzheimer's. When faced with an immune challenge, these microglia exhibited reduced mitochondrial ATP production and a decreased release of inflammatory cytokines like IL-6 and TNF. There was also a marked deficit in the uptake of amyloid-beta, a protein linked to Alzheimer's pathology.
Why it matters
The findings indicate that microglial dysfunction could be crucial in Alzheimer's disease even before amyloid plaques form. By employing iPSC models, researchers can gain a clearer understanding of the early changes in Alzheimer's pathogenesis, potentially leading to new therapeutic strategies. This study also highlights the potential of using such models for screening drugs and genetic therapies aimed at addressing microglial impairments.
Discover more from Neurospan
Subscribe to get the latest posts sent to your email.
